Intratympanic gentamicin for treatment of intractable Meniere's disease: a preliminary report.
Topical administration of aminoglycoside antibiotics in the middle ear can achieve "chemical labyrinthectomy" in patients with intractable Meniere's disease. Herein we report our results of intratympanic gentamicin therapy in 21 patients using two different dosing protocols, twice weekly and twice daily (b.i.d.). Both hearing and vertigo outcome were evaluated. Complete control of episodic vertigo was achieved initially in 20 of 21 patients (95.2%). However, 6 of 20 responders (30%) developed relapsing symptoms within 12 months. Retreatment was successful in 75% of these patients. Overall, hearing was preserved or improved in 62% of cases, worse in 24%, and not yet tested in 14%. When the cumulative dose of gentamicin was < or = 4 injections in the first week, only 1 of 14 (7.1%) lost hearing. Intratympanic gentamicin offers better risk/benefit outcome than other invasive therapies for intractable Meniere's disease.
Rauch
S D
SD
Department of Otology and Laryngology, Harvard Medical School and Massachusetts Eye and Ear Infirmary, Boston 02114, USA.
Oas
J G
JG
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D005260:Female; D005839:Gentamicins / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008575:Meniere Disease / Q000188:drug therapy* / Q000503:physiopathology; D008875:Middle Aged; D016896:Treatment Outcome; D014432:Tympanic Membrane; D014724:Vestibular Function Tests
D000900:Anti-Bacterial Agents; D005839:Gentamicins